Christoph Bieri
Christoph Bieri, PhD is Managing Partner of Kurmann Partners www.kurmannpartners.com, an M&A firm advising Pharma and MedTech companies on strategic mid-market deals in Europe and the Americas. Mr. Bieri has extensive experience in leading complex transactions, both as a buy-side and sell-side advisor, and regularly presents and publishes analyses of drivers of M&A in the life science industries.
Prior to joining Kurmann Partners, Christoph was founder and CEO of a drug discovery technology company, and before that a senior associate with The Boston Consulting Group. He holds a PhD in Biophysics from ETH Lausanne and a Master in Biochemistry from the Biocenter of the University of Basel.
Christoph Bieri, PhD is Managing Partner of Kurmann Partners www.kurmannpartners.com, an M&A firm advising Pharma and MedTech companies on strategic mid-market deals in Europe and the Americas. Mr. Bieri has extensive experience in leading complex transactions, both as a buy-side and sell-side advisor, and regularly presents and publishes analyses of drivers of M&A in the life science industries.
Prior to joining Kurmann Partners, Christoph was founder and CEO of a drug discovery technology company, and before that a senior associate with The Boston Consulting Group. He holds a PhD in Biophysics from ETH Lausanne and a Master in Biochemistry from the Biocenter of the University of Basel.
Articles: Christoph Bieri
Year in Review – Transformational Transactions Dominated 2018
Opinion / Christoph Bieri, PhD is Managing Partner of Kurmann Partners, an M&A firm advising Pharma and MedTech companies on strategic mid-market deals in Europe and the Americas. In this article, Bieri looks back on the stand out deals of 2018 and gives his insights into 2019. Sentiment in the industry is that we will see large…
Novartis’ M&A Saga and What it Could Mean for Sandoz
Opinion / Christoph Bieri, PhD is Managing Partner of Kurmann Partners, an M&A firm advising Pharma and MedTech companies on strategic mid-market deals in Europe and the Americas. Here he looks at Novartis’ bold M&A moves and what they could mean for their generics arm, Sandoz. Besides the large business platform acquisitions, Novartis has always been…
M&A by necessity: Takeda and Shire
regulation / The stakes are high, and the outcome is uncertain in one of the largest Pharma M&A deals ever. Takeda’s proposed acquisition of Shire seems to have it all: The combined entity becoming one of the largest global Pharma groups, enabling Takeda to become a truly global operation and allowing Shire’s shareholders to get a very…
